Our first-in-human study results indicate that ARGX-111 is safe in advanced cancer patients, and the drug showed signs of therapeutic activity in MET-overexpressing tumors as well as MET-amplified tumors based on its unique Modes of Action, thereby supporting further clinical development of the antibody as monotherapy or in combination. This evidence concerns the gene MET and cancer.